SONNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (19 4月 2024 @ 05:00):

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action...

Stats
本日の出来高	17 032.00
平均出来高	103 724
時価総額	5.43M
EPS	$0 ( 2024-02-14 )
次の収益日	( $0.130 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.13
ATR14	$0.00800 (0.46%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-27	Rao Raghu	Buy	31 250	Warrant to Purchase Common Stock
2023-10-27	Rao Raghu	Buy	15 625	Common Stock
2023-10-27	Mohan Pankaj	Buy	68 750	Warrant to Purchase Common Stock
2023-10-27	Mohan Pankaj	Buy	34 375	Common Stock
2023-08-07	Markey John	Sell	0	Common Stock

INSIDER POWER
82.18
Last 88 transactions
Buy: 5 035 351 \| Sell: 2 861 714

ボリューム相関

長: -0.01 (neutral)

短: 0.78 (moderate)

Signal:(51.118) Neutral

Sonnet Biotherapeutics 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Sonnet Biotherapeutics 相関 - 通貨/商品

-0.54
( weak negative )

-0.39
( neutral )

0.00
( neutral )

-0.15
( neutral )

0.66
( moderate )

0.14
( neutral )

Sonnet Biotherapeutics 財務諸表

Annual	2023
収益:	$147 805
総利益:	$72 055.00 (48.75 %)
EPS:	$-18.14

Q4	2023
収益:	$37 255.00
総利益:	$17 789.00 (47.75 %)
EPS:	$-2.10

Q3	2023
収益:	$36 850.00
総利益:	$17 873.00 (48.50 %)
EPS:	$-2.96

Q2	2023
収益:	$36 445.00
総利益:	$17 572.00 (48.22 %)
EPS:	$-7.56

Financial Reports:

No articles found.

Sonnet Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.